Ipilimumab 50mg/10mL (5mg/mL) Injection

Ipilimumab 50mg/10mL is an immune-checkpoint inhibitor used for melanoma and selected renal-cell, lung, colorectal and other cancer regimens, often in combination with nivolumab.
It is diluted and given by intravenous infusion on the cancer-specific schedule. The regimen may include another immune-checkpoint medicine, with separate monitoring requirements.
Ipilimumab blocks CTLA-4, releasing an inhibitory signal that normally limits activation of T cells.
Rash, itching, diarrhoea and tiredness can occur. Immune-mediated colitis, hepatitis, hormone-gland inflammation and other organ inflammation can be serious.
New diarrhoea, severe abdominal pain, jaundice or persistent headache requires early assessment. Immune-related problems can develop during treatment or after it has stopped.
Can produce durable immune-mediated cancer control in a proportion of eligible patients.
Its main effect is to increase immune activity by blocking an immune checkpoint.
It can indicate immune-mediated colitis, which can worsen if treatment is delayed.
Yes. Immune injury to the pituitary, thyroid or adrenal glands can cause persistent hormone deficiencies.
Yes. Immune activation and organ inflammation may become apparent after treatment ends.
CTLA-4: an inhibitory receptor on T cells. Immune checkpoint: a mechanism limiting immune activity. Colitis: inflammation of the large intestine.; AR: Ipilimumab 50mg/10mL (5mg/mL) حقن; FR: Ipilimumab 50mg/10mL (5mg/mL) injection; PT: Ipilimumab 50mg/10mL (5mg/mL) injeção; ES: Ipilimumab 50mg/10mL (5mg/mL) inyección; RU: Ipilimumab 50mg/10mL (5mg/mL) инъекция; ID: Ipilimumab 50mg/10mL (5mg/mL) injeksi; VI: Ipilimumab 50mg/10mL (5mg/mL) thuốc tiêm; MS: Ipilimumab 50mg/10mL (5mg/mL) suntikan; TL: Ipilimumab 50mg/10mL (5mg/mL) iniksyon; ZH-SG: Ipilimumab 50mg/10mL (5mg/mL) 注射剂
International B2B Enquiry
Send a structured B2B enquiry for Ipilimumab 50mg/10mL (5mg/mL) Injection under Oncology Care. Global Medicines Export helps international buyers review product information, pack details, quantity requirements, destination-market needs, quotation support and export documentation coordination from India.
Product name, required strength or pack, expected quantity, destination country, buyer type and preferred manufacturer if any.
Availability, quotation support, documentation expectations and shipment-ready order communication can be reviewed before confirmation.
Commercial invoice, packing information, manufacturer details, batch details and supporting documents where applicable and available.
Product availability, quotation, and documentation support are coordinated for international B2B enquiries.
Ipilimumab 50mg/10mL (5mg/mL) Injection